TP53 and neoplasm: However, truncating TP53 mutations (such as nonsense mutations) may completely abolish transcriptional regulation, leading to decreased tumor mutation burden (TMB) or loss of PD-L1 expression, which in turn predicts immunotherapy resistance (72).